Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024
High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) is a condition that is typically treated with Bacillus Calmette-Guérin (BCG) therapy. Unfortunately, NMIBC is characterized by high recurrence, with a significant percentage of BCG patients ultimately requiring radical cystectomy....
Saved in:
Main Authors: | Feng Qu (Author), Saloni Darji (Author), David H. Thompson (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Novel therapies of treating non-muscle invasive bladder cancer when BCG therapy turns out to be insufficient
by: Magdalena Kołodziej, et al.
Published: (2024) -
Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis
by: Quignot N, et al.
Published: (2023) -
A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients
by: Mark Kowalski, et al.
Published: (2010) -
Applications of Exosomes in Diagnosing Muscle Invasive Bladder Cancer
by: Jillian Marie Walker, et al.
Published: (2022) -
Recent Advances in Minimally Invasive Surgery
Published: (2021)